Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Risk of Adverse Pregnancy Outcome After Paternal Exposure to Methotrexate Within 90 Days Before Pregnancy

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibodies at Delivery in Women, Partners, and Newborns

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Human Papillomavirus Genotypes From Vaginal and Vulvar Intraepithelial Neoplasia in Females 15-26 Years of Age

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Risk of Adverse Pregnancy Outcomes at Advanced Maternal Age

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Association Between Menopausal Estrogen-Only Therapy and Ovarian Carcinoma Risk

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Low-dose aspirin for primary and secondary prevention of cardiovascular events in Denmark 1998-2018

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Treatment of Hyperthyroidism Reduces Systemic Oxidative Stress, as Measured by Markers of RNA and DNA Damage

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Insulin resistance genetic risk score and burden of coronary artery disease in patients referred for coronary angiography

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

OBJECTIVE: To study the association between paternal exposure to methotrexate within the 90-day period before pregnancy and congenital malformations and stillbirth in the offspring.

METHODS: We conducted a nationwide register study. Our cohort consisted of all live births in Denmark between 1997 and 2011 identified from the Medical Birth Registry. Methotrexate-exposed fathers were identified from the National Prescription Registry. From the national Hospital Registry we identified paternity, live births, and stillbirths as well as discharge diagnoses on congenital malformations.

RESULTS: We identified 849,676 live births with known paternity. There were 127 live births of methotrexate-exposed fathers. Of these, four (3.2%) had major malformations compared with 28,814 (3.4%) of the unexposed. The odds ratio (OR) for major congenital malformation among exposed fathers compared with unexposed was 0.93 (95% confidence interval [CI] 0.34-2.51) and when adjusted for year of birth, maternal age, educational length, household income, and parity, the adjusted OR was 1.01 (95% CI 0.37-2.74). There were no stillbirths in the methotrexate-exposed group compared with 2,541 (0.3%) in the unexposed group and no increased risk of preterm birth (adjusted OR 1.31, 95% CI 0.66-2.59) among the children from exposed fathers.

CONCLUSION: We found no association between paternal exposure to methotrexate within 90 days before pregnancy and congenital malformations, stillbirths, or preterm birth. Available data suggest that prepregnancy paternal methotrexate exposure should not be of major concern. Multinational recommendations should be changed accordingly.

Original languageEnglish
JournalObstetrics and Gynecology
Volume129
Issue number4
Pages (from-to)707-714
ISSN0029-7844
DOIs
Publication statusPublished - 1 Apr 2017

    Research areas

  • Journal Article

ID: 50109122